Granules Q1 net rises on formulations

Our Bureau Hyderabad | Updated on March 12, 2018 Published on July 28, 2011

Driven by improved performance of the formulations division, especially the demand for metformin, Granules India Ltd (GIL) logged a 63 per cent growth in net profit at Rs 3 crore (Rs 2 crore) for the first quarter ended June 30, 2011.

The formulations contributed Rs 37 crore in a turnover of Rs 119 crore for the quarter (Rs 109 crore).

Expansion complete

Granules, an integrated formulations manufacturer, expects growth in Q2 and Q3 riding on its ibuprofen, a press release said.

In addition, the company completed the expansion of a new PFI (pharmaceutical formulation intermediates) module, which will increase capacity by 1,200 tonnes annually.

The company is also on track to finish an 8,000 tonnes annually PFI module and a 12 billion dosage formulation module by the end of the fiscal year.

The basic EPS was Rs 1.56 for the quarter (Rs 0.96).

Published on July 28, 2011
This article is closed for comments.
Please Email the Editor